ImmunityBio, Inc. Common Stock
IBRX Real Time Price USDRecent trades of IBRX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel S. Goldman House / D | Sale $1,001 - $15,000 | Mar 06, 2023 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by IBRX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$45,000 Oct 08, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$45,000 Jul 19, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$60,000 Apr 09, 2022 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$60,000 Jan 17, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
IBRX Revenue by Segment or Geography
New patents grants
-
Patent Title: Distributed ledger for medicament administration tracking Apr. 08, 2025
-
Patent Title: Multi-chain chimeric polypeptides and uses thereof Apr. 08, 2025
-
Patent Title: Mononuclear cell derived nk cells Feb. 04, 2025
-
Patent Title: Advanced avatar dendritic cells Jan. 14, 2025
-
Patent Title: Chromatography resin and uses thereof Jan. 07, 2025
-
Patent Title: Methods and systems for producing a protein of interest in a plant Dec. 31, 2024
-
Patent Title: Nant covid vaccine cross reactivity Dec. 17, 2024
-
Patent Title: Methods of treating age-related and inflammatory diseases Oct. 15, 2024
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells Oct. 08, 2024
-
Patent Title: Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags Sep. 10, 2024
-
Patent Title: Tumoricidal and antimicrobial compositions and methods Aug. 20, 2024
-
Patent Title: Advanced avatar dendritic cells Jul. 23, 2024
-
Patent Title: Nant covid vaccine cross reactivity Jun. 25, 2024
-
Patent Title: Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment May. 28, 2024
-
Patent Title: Tumoricidal and antimicrobial compositions and methods May. 07, 2024
-
Patent Title: Generating cik nkt cells from cord blood Mar. 19, 2024
-
Patent Title: Method of inducing immunity against sars-cov-2 using spike (s) and nucleocapsid (n)-etsd immunogens delivered by a replication-defective adenovirus Jan. 02, 2024
-
Patent Title: Modified nk-92 hank003 cells for the clinic Sep. 12, 2023
-
Patent Title: Fc-epsilon car May. 09, 2023
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells Jan. 10, 2023
-
Patent Title: Mononuclear cell derived nk cells Sep. 27, 2022
-
Patent Title: Generating cik nkt cells from cord blood Jun. 07, 2022
-
Patent Title: Tumoricidal and antimicrobial compositions and methods Apr. 19, 2022
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors Jan. 25, 2022
-
Patent Title: Tumoricidal and antimicrobial compositions and methods Jan. 04, 2022
-
Patent Title: Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer Dec. 28, 2021
-
Patent Title: Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies Sep. 28, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to IBRX
Recent picks made for IBRX stock on CNBC
ETFs with the largest estimated holdings in IBRX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IBRX stock a Buy, Sell, or Hold?
- What is the price target for $IBRX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IBRX stock?
- Who owns the most shares of $IBRX stock?
- What funds own $IBRX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IBRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.